Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab

OBJECTIVES: To report clinical outcome, development of humoral and T-cell mediated immunity in convalescent COVID-19 people with multiple sclerosis (pwMS) treated with ofatumumab in the ALITHIOS study from a single center. METHODS: Testing for SARS-Cov2 IgG antibodies was performed on two occasions...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamec, Ivan, Rogić, Dunja, Penz, Monika-Gabriele, Braun, Carola, Habek, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667348/
https://www.ncbi.nlm.nih.gov/pubmed/34922128
http://dx.doi.org/10.1016/j.jneuroim.2021.577788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667348/
https://www.ncbi.nlm.nih.gov/pubmed/34922128
http://dx.doi.org/10.1016/j.jneuroim.2021.577788

Ejemplares similares